<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02500849</url>
  </required_header>
  <id_info>
    <org_study_id>14017</org_study_id>
    <nct_id>NCT02500849</nct_id>
  </id_info>
  <brief_title>Safety Study of Zinc Finger Nuclease CCR5-modified Hematopoietic Stem/Progenitor Cells in HIV-1 Infected Patients</brief_title>
  <official_title>A Pilot Study to Evaluate the Feasibility, Safety and Engraftment of Zinc Finger Nuclease (ZFN) CCR5 Modified CD34+ Hematopoietic Stem/Progenitor Cells (SB-728mR-HSPC) in HIV-1 (R5) Infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>City of Hope Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sangamo Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>California Institute for Regenerative Medicine (CIRM)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>City of Hope Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the safety and feasibility of administering&#xD;
      SB-728mR-HSPC after conditioning with busulfan.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of the study is to evaluate the safety and feasibility of giving autologous&#xD;
      SB-728mR-HSPC to HIV-1 (R5) infected patients who are being treated with cART and have&#xD;
      undetectable virus but suboptimal CD4+ cell levels. To strengthen the possibility that&#xD;
      CCR5-disrupted HSPCs engraft, patients will receive either a two- or three-day (Cohort 1 or&#xD;
      Cohort 2) course of busulfan (dose targeting AUC of 4000 µM/day) before being infused with&#xD;
      the genetically modified cells. At 9-12 months after SB-728mR-HSPC infusion, subjects who are&#xD;
      aviremic with CD4 cell counts ≥600 cells/µL and have ≥1% CCR5-modified CD4 cells within the&#xD;
      peripheral blood detected by pentamer PCR will undergo an ATI.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 10, 2016</start_date>
  <completion_date type="Anticipated">December 10, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 10, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity in subjects who received SB-728mR-HSPC after each busulfan dose level</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of CD34+ HSPC collected, gene modified, and released throughout the manufacturing process</measure>
    <time_frame>Approximately first 1-2 months on study</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Detection of CCR5 modified HSPC in bone marrow</measure>
    <time_frame>Up to Month 12</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Time to hematological recovery as measured by neutrophil and platelet engraftment time</measure>
    <time_frame>Up to Year 5</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Changes in CD4+ T-cell percentage after SB-728mR-HSPC infusion</measure>
    <time_frame>Up to Year 5</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Changes in CD4+ T-cell number after SB-728mR-HSPC infusion</measure>
    <time_frame>Up to Year 5</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Changes in CD4/CD8 ratio after SB-728mR-HSPC infusion</measure>
    <time_frame>Up to Year 5</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Detection of CCR5-modified PBMC in blood over time</measure>
    <time_frame>Up to Year 5</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>HIV-1 RNA levels in plasma during the treatment interruption of antiretroviral medicines</measure>
    <time_frame>ATI Day 0 and weeks 2, 4, 6, 8, 10, 12, 14, 16 and 28</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Longitudinal changes of proviral DNA in PBMC</measure>
    <time_frame>18 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacokinetic analysis of busulfan (AUC levels)</measure>
    <time_frame>pre-busulfan and at 15, 30, 60, 180 and 240 min after end of infusion</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Cohort 1:</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>target busulfan AUC levels: 8,000 µM*min (+/- 1,000)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2:</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>busulfan AUC levels: 12,000 µM*min (+/- 1,000)</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>SB-728mR-HSPC Infusion 3 days following busulfan conditioning</intervention_name>
    <arm_group_label>Cohort 1:</arm_group_label>
    <arm_group_label>Cohort 2:</arm_group_label>
    <other_name>busulfan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Maximum age 75 years for cohort 1 and 65 years for cohort 2.&#xD;
&#xD;
          -  HIV-1 R5 seropositive with no evidence of CXCR4-tropic virus.&#xD;
&#xD;
          -  On cART with undetectable HIV-1 (&lt;20 gc/ml HIV-1 RNA) for at least 12 months prior to&#xD;
             screening evaluations.&#xD;
&#xD;
          -  CD4+ T-cell counts ≥200 cells/µL and ≤750 cells/µL.&#xD;
&#xD;
          -  No psychosocial conditions that would hinder study compliance and follow-up.&#xD;
&#xD;
          -  Absence of clinically significant cardiomyopathy, congestive heart failure.&#xD;
&#xD;
        Secondary Eligibility Criteria (for registration):&#xD;
&#xD;
          -  Complete G-CSF/Plerixafor mobilization of HSPC.&#xD;
&#xD;
          -  Collect ≥7.5 x 10^6 CD34+ cells/kg in two aphereses.&#xD;
&#xD;
          -  The SB-728mR-HSPC product passed all release testing&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of AZT or maraviroc in the cART regimen.&#xD;
&#xD;
          -  History of significant hematologic diseases such as leukemia, myelodysplasia,&#xD;
             coagulopathy, and thromboembolism.&#xD;
&#xD;
          -  Any AIDS-related opportunistic infection occurring within the past year such as&#xD;
             tuberculosis, cryptococcosis and for which treatment has been unsuccessful as&#xD;
             determined by the Principal Investigator.&#xD;
&#xD;
          -  AIDS-related syndromes, infectious or otherwise, if perceived to cause excessive risk&#xD;
             for morbidity post-HSPC infusion, as determined by the Principal Investigator.&#xD;
&#xD;
          -  Patients with active HBV or HCV infection, i.e., HBV DNA and HCV RNA in blood, are&#xD;
             excluded. Those with inactive, but past infection with HBV (positive HBV surface&#xD;
             antigen or HBV surface antibody) or inactive HCV (positive HCV antibody), must have no&#xD;
             cirrhosis, as determined by abdominal ultrasound with elastography.&#xD;
&#xD;
          -  Active CMV retinitis or other active CMV-related organ dysfunction.&#xD;
&#xD;
          -  CXCR4-tropic virus.&#xD;
&#xD;
          -  Pregnant or nursing women.&#xD;
&#xD;
          -  Any history of HIV-associated encephalopathy; dementia of any kind; seizures in the&#xD;
             past 12 months; any perceived inability to directly provide informed consent.&#xD;
&#xD;
          -  Participants may not be receiving any other investigational agents, or concurrent&#xD;
             biological, chemotherapy, or radiation therapy. Participation in prior investigational&#xD;
             drug or medical device study within the previous 45 days.&#xD;
&#xD;
          -  Current or history of immunomodulatory agent or steroid use.&#xD;
&#xD;
          -  Prior therapy with HIV vaccine or gene therapy product.&#xD;
&#xD;
          -  History of alcohol or substance abuse for the previous 12 months.&#xD;
&#xD;
          -  Participants with active malignancies. However, participants with skin cancers, namely&#xD;
             basal cell or squamous cell carcinoma, and malignancies treated with curative intent&#xD;
             having no known active disease present for ≥2 years, may be eligible.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amrita Y. Krishnan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>City of Hope Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA CARE Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mills Clinical Research</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quest Clinical Research</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Circle CARE Center, LLC</name>
      <address>
        <city>Norwalk</city>
        <state>Connecticut</state>
        <zip>06850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 16, 2015</study_first_submitted>
  <study_first_submitted_qc>July 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2015</study_first_posted>
  <last_update_submitted>August 10, 2021</last_update_submitted>
  <last_update_submitted_qc>August 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gene therapy</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>HIV Infections</keyword>
  <keyword>Retroviridae Infections</keyword>
  <keyword>RNA Virus Infections</keyword>
  <keyword>Virus Diseases</keyword>
  <keyword>Sexually Transmitted Diseases, Viral</keyword>
  <keyword>Sexually Transmitted Diseases</keyword>
  <keyword>Immunologic Deficiency Syndromes</keyword>
  <keyword>Immune System Diseases</keyword>
  <keyword>Busulfan</keyword>
  <keyword>Pharmacologic Actions</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Busulfan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

